Company profile for Kodiak Sciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ophthalmic diseases. Our team has the diversity of experience to build a leading biotech company. At Kodiak, we are working to develop disruptive products and platforms to prevent and treat the leading causes of blindness. Our biologics-based medicines are built on a proprietary high science Antibody Biopolyme...
We are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ophthalmic diseases. Our team has the diversity of experience to build a leading biotech company. At Kodiak, we are working to develop disruptive products and platforms to prevent and treat the leading causes of blindness. Our biologics-based medicines are built on a proprietary high science Antibody Biopolymer Conjugate or ABC Platform designed to maintain potent and effective drug levels in key ocular tissues for longer than currently available therapies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2631 HANOVER STREET PALO ALTO, CA 94304
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/kodiak-sciences-announces-recent-business-highlights-and-third-quarter-2025-financial-results-302615021.html

PR NEWSWIRE
13 Nov 2025

https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-investor-conferences-302613755.html

PR NEWSWIRE
12 Nov 2025

https://www.prnewswire.com/news-releases/follow-up-data-for-kodiaks-ksi-101-from-the-apex-study-showed-continued-strengthening-of-clinical-effect-90-of-patients-achieving-absence-of-intraretinal-and-subretinal-fluid-through-week-20-in-macular-edema-secondary-to-infl-302605063.html

PR NEWSWIRE
05 Nov 2025

https://www.prnewswire.com/news-releases/new-data-for-kodiaks-ksi-101-from-the-apex-study-reinforce-its-clinically-meaningful-vision-gains-and-rapid-retinal-drying-in-macular-edema-secondary-to-inflammation-mesi-302555986.html

PR NEWSWIRE
15 Sep 2025

https://www.prnewswire.com/news-releases/kodiak-sciences-to-participate-in-upcoming-scientific-conferences-highlighting-ksi-101-in-patients-with-macular-edema-secondary-to-inflammation-mesi-302543483.html

PR NEWSWIRE
02 Sep 2025

https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-american-chemical-society-fall-2025-302533816.html

PR NEWSWIRE
19 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty